INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) revealed long-term study results indicating that over 80% of adults and adolescents with moderate-to-severe atopic dermatitis maintained clear or nearly clear skin after up to three years of monthly EBGLYSS treatment. These findings from the ADjoin extension study will be presented at the European Academy of Dermatology and Venereology Congress in Amsterdam.
EBGLYSS, an interleukin-13 (IL-13) inhibitor, has been shown to effectively block the signaling pathways of the cytokine IL-13, which is a key driver of atopic dermatitis. The latest data suggests that nearly 87% of patients did not need high-potency topical corticosteroids or systemic treatments during the trial.
The safety profile of EBGLYSS over the three-year period remained consistent with the two-year results, showing no new safety concerns. The majority of adverse events were mild or moderate, with less than three percent of patients discontinuing treatment due to side effects.
The study included patients who had responded to EBGLYSS by Week 16 in the ADvocate 1 and 2 trials and continued with either 250 mg every two weeks or once monthly for up to 152 weeks. The approved maintenance dose for EBGLYSS is 250 mg once monthly. The analysis showed that 84 percent of patients on the monthly regimen and 83 percent on the biweekly regimen maintained clear or almost-clear skin after three years.
Eli Lilly's partner Almirall holds the rights to develop and commercialize EBGLYSS for dermatology indications in Europe, while Lilly retains rights elsewhere. EBGLYSS was approved by the FDA earlier this month and received approval in the European Union in 2023 and Japan in January 2024.
The company plans to present additional data from ongoing clinical studies at future medical congresses. EBGLYSS's recent approvals and the promising results of this extension study highlight its potential as a long-term treatment option for those suffering from moderate-to-severe atopic dermatitis. This information is based on a press release statement.
In other recent news, Eli Lilly and Company's Alzheimer's treatment, donanemab, known as Kisunla, has been approved in Japan. The approval presents a new treatment option for the rising number of Alzheimer's patients in the country. Kisunla demonstrated a 29% reduction in the progression of memory and cognitive issues in a significant late-stage trial. However, the drug has been associated with mild cases of brain swelling and bleeding in some patients.
Meanwhile, Deutsche Bank maintained a positive stance on Eli Lilly shares, reiterating a Buy rating after the release of Phase 2a study results for a competing drug, monlunabant, by Novo Nordisk (NYSE:NVO). Eli Lilly's own drug candidate, orforglipron, demonstrated more promising results in similar trials, positioning it favorably against monlunabant.
The FDA has approved Eli Lilly's new eczema treatment, EBGLYSS, based on results from three clinical studies. BMO Capital also maintained its Outperform rating on Eli Lilly shares, highlighting the company's commitment to enhancing its manufacturing capabilities. The company's phase 3 trial for the once-weekly insulin efsitora demonstrated successful A1C reduction in adults with type 2 diabetes who are initiating insulin therapy. These are recent developments from Eli Lilly.
InvestingPro Insights
Eli Lilly and Company's (NYSE: LLY) recent announcement regarding the long-term efficacy of EBGLYSS has been met with optimism in the pharmaceutical community. This positive sentiment is reflected in the company's financial metrics and analyst forecasts. InvestingPro data shows a robust revenue growth of 31.87% over the last twelve months as of Q2 2024, indicating a strong market demand for their products, including EBGLYSS. The company's commitment to innovation and patient care is also evident in its significant gross profit margin of 80.75% during the same period, which suggests efficient cost management and a solid competitive advantage.
Furthermore, Eli Lilly's dedication to shareholder returns is highlighted by the fact that it has raised its dividend for 9 consecutive years, with the latest dividend growth reported at 15.04%. This could be a reassuring sign for investors looking for stable income in addition to capital gains. An InvestingPro Tip also notes that Eli Lilly is a prominent player in the Pharmaceuticals industry, which aligns with their recent achievements and strategic partnerships for EBGLYSS.
Despite trading at a high earnings multiple, with a P/E ratio of 113.19, the company's net income is expected to grow this year, and 18 analysts have revised their earnings upwards for the upcoming period. This optimism is further supported by the company's strong return over the last year, with a price total return of 68.51%. For investors and analysts seeking more in-depth insights, there are additional InvestingPro Tips available at https://www.investing.com/pro/LLY, which could provide a more comprehensive understanding of Eli Lilly's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.